nodes	percent_of_prediction	percent_of_DWPC	metapath
Zafirlukast—CYP2C8—Tazarotene—psoriasis	0.0672	0.0905	CbGbCtD
Zafirlukast—CYP1A2—Clobetasol propionate—psoriasis	0.0638	0.0859	CbGbCtD
Zafirlukast—ABCG2—Mycophenolate mofetil—psoriasis	0.0467	0.0629	CbGbCtD
Zafirlukast—ABCG2—Hydrocortisone—psoriasis	0.0375	0.0505	CbGbCtD
Zafirlukast—ABCG2—Cyclosporine—psoriasis	0.0354	0.0476	CbGbCtD
Zafirlukast—CYP1A2—Methoxsalen—psoriasis	0.0335	0.0451	CbGbCtD
Zafirlukast—CYP2D6—Hydroxyurea—psoriasis	0.0302	0.0407	CbGbCtD
Zafirlukast—CYP2C8—Cholecalciferol—psoriasis	0.0287	0.0386	CbGbCtD
Zafirlukast—CYP2C8—Mycophenolate mofetil—psoriasis	0.0249	0.0335	CbGbCtD
Zafirlukast—CYP2C19—Cholecalciferol—psoriasis	0.0241	0.0324	CbGbCtD
Zafirlukast—ABCG2—Dexamethasone—psoriasis	0.0233	0.0314	CbGbCtD
Zafirlukast—CYP3A4—Calcitriol—psoriasis	0.0226	0.0304	CbGbCtD
Zafirlukast—CYP2C9—Cholecalciferol—psoriasis	0.02	0.0269	CbGbCtD
Zafirlukast—CYP2C8—Hydrocortisone—psoriasis	0.02	0.0269	CbGbCtD
Zafirlukast—CYP2C8—Cyclosporine—psoriasis	0.0188	0.0254	CbGbCtD
Zafirlukast—ABCG2—Methotrexate—psoriasis	0.0187	0.0252	CbGbCtD
Zafirlukast—CYP2D6—Cholecalciferol—psoriasis	0.0183	0.0246	CbGbCtD
Zafirlukast—CYP3A4—Methoxsalen—psoriasis	0.0176	0.0236	CbGbCtD
Zafirlukast—CYP2C19—Prednisone—psoriasis	0.0167	0.0225	CbGbCtD
Zafirlukast—CYP2E1—Dexamethasone—psoriasis	0.0166	0.0224	CbGbCtD
Zafirlukast—CYP2C19—Cyclosporine—psoriasis	0.0158	0.0213	CbGbCtD
Zafirlukast—CYP2C9—Cyclosporine—psoriasis	0.0131	0.0177	CbGbCtD
Zafirlukast—CYP2C8—Dexamethasone—psoriasis	0.0124	0.0167	CbGbCtD
Zafirlukast—CYP2D6—Cyclosporine—psoriasis	0.012	0.0162	CbGbCtD
Zafirlukast—CYP3A4—Cholecalciferol—psoriasis	0.0116	0.0157	CbGbCtD
Zafirlukast—CYP2C19—Dexamethasone—psoriasis	0.0104	0.014	CbGbCtD
Zafirlukast—CYP3A4—Mycophenolate mofetil—psoriasis	0.0101	0.0136	CbGbCtD
Zafirlukast—CYP3A4—Triamcinolone—psoriasis	0.0101	0.0136	CbGbCtD
Zafirlukast—CYP2C9—Dexamethasone—psoriasis	0.00866	0.0117	CbGbCtD
Zafirlukast—CYP3A4—Betamethasone—psoriasis	0.00865	0.0117	CbGbCtD
Zafirlukast—CYP3A4—Prednisolone—psoriasis	0.00854	0.0115	CbGbCtD
Zafirlukast—CYP3A4—Hydrocortisone—psoriasis	0.00809	0.0109	CbGbCtD
Zafirlukast—CYP3A4—Prednisone—psoriasis	0.00806	0.0109	CbGbCtD
Zafirlukast—CYP2D6—Dexamethasone—psoriasis	0.00792	0.0107	CbGbCtD
Zafirlukast—CYP3A4—Cyclosporine—psoriasis	0.00764	0.0103	CbGbCtD
Zafirlukast—CYP3A4—Dexamethasone—psoriasis	0.00503	0.00678	CbGbCtD
Zafirlukast—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00223	0.0464	CbGpPWpGaD
Zafirlukast—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00193	0.0401	CbGpPWpGaD
Zafirlukast—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00172	0.0358	CbGpPWpGaD
Zafirlukast—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00158	0.0329	CbGpPWpGaD
Zafirlukast—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00157	0.0326	CbGpPWpGaD
Zafirlukast—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00148	0.0307	CbGpPWpGaD
Zafirlukast—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00138	0.0287	CbGpPWpGaD
Zafirlukast—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.0012	0.0248	CbGpPWpGaD
Zafirlukast—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00107	0.0222	CbGpPWpGaD
Zafirlukast—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000981	0.0204	CbGpPWpGaD
Zafirlukast—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000973	0.0202	CbGpPWpGaD
Zafirlukast—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000973	0.0202	CbGpPWpGaD
Zafirlukast—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000831	0.0173	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—HCAR2—psoriasis	0.000741	0.0154	CbGpPWpGaD
Zafirlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000674	0.014	CbGpPWpGaD
Zafirlukast—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000641	0.0133	CbGpPWpGaD
Zafirlukast—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000623	0.0129	CbGpPWpGaD
Zafirlukast—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000574	0.0119	CbGpPWpGaD
Zafirlukast—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000567	0.0118	CbGpPWpGaD
Zafirlukast—ABCG2—Iron uptake and transport—CP—psoriasis	0.000534	0.0111	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—HCAR2—psoriasis	0.000513	0.0107	CbGpPWpGaD
Zafirlukast—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000505	0.0105	CbGpPWpGaD
Zafirlukast—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000496	0.0103	CbGpPWpGaD
Zafirlukast—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00049	0.0102	CbGpPWpGaD
Zafirlukast—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000465	0.00968	CbGpPWpGaD
Zafirlukast—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.00046	0.00956	CbGpPWpGaD
Zafirlukast—CYSLTR2—Endothelins—JUN—psoriasis	0.000457	0.00951	CbGpPWpGaD
Zafirlukast—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000443	0.00921	CbGpPWpGaD
Zafirlukast—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000437	0.00909	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR downstream signaling—HCAR2—psoriasis	0.000419	0.0087	CbGpPWpGaD
Zafirlukast—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000407	0.00847	CbGpPWpGaD
Zafirlukast—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000404	0.0084	CbGpPWpGaD
Zafirlukast—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000402	0.00836	CbGpPWpGaD
Zafirlukast—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000402	0.00836	CbGpPWpGaD
Zafirlukast—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000399	0.00829	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR ligand binding—CCL20—psoriasis	0.000385	0.008	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—HCAR2—psoriasis	0.00038	0.0079	CbGpPWpGaD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000379	0.00789	CbGpPWpGaD
Zafirlukast—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000359	0.00746	CbGpPWpGaD
Zafirlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00035	0.00728	CbGpPWpGaD
Zafirlukast—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000345	0.00717	CbGpPWpGaD
Zafirlukast—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000341	0.00708	CbGpPWpGaD
Zafirlukast—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000331	0.00688	CbGpPWpGaD
Zafirlukast—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00033	0.00687	CbGpPWpGaD
Zafirlukast—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000327	0.00681	CbGpPWpGaD
Zafirlukast—CYSLTR1—Endothelins—JUN—psoriasis	0.000317	0.00659	CbGpPWpGaD
Zafirlukast—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000299	0.00622	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR downstream signaling—HCAR2—psoriasis	0.00029	0.00603	CbGpPWpGaD
Zafirlukast—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00028	0.00582	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR ligand binding—CCL20—psoriasis	0.000267	0.00554	CbGpPWpGaD
Zafirlukast—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000266	0.00554	CbGpPWpGaD
Zafirlukast—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000264	0.00548	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—HCAR2—psoriasis	0.000263	0.00548	CbGpPWpGaD
Zafirlukast—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000263	0.00546	CbGpPWpGaD
Zafirlukast—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000247	0.00514	CbGpPWpGaD
Zafirlukast—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000244	0.00507	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—HCAR2—psoriasis	0.000225	0.00467	CbGpPWpGaD
Zafirlukast—Discomfort—Mycophenolate mofetil—psoriasis	0.000224	0.00107	CcSEcCtD
Zafirlukast—Oedema—Cyclosporine—psoriasis	0.000223	0.00106	CcSEcCtD
Zafirlukast—Angioedema—Hydrocortisone—psoriasis	0.000222	0.00106	CcSEcCtD
Zafirlukast—Infection—Cyclosporine—psoriasis	0.000222	0.00106	CcSEcCtD
Zafirlukast—Back pain—Triamcinolone—psoriasis	0.000221	0.00106	CcSEcCtD
Zafirlukast—Malaise—Hydrocortisone—psoriasis	0.000219	0.00105	CcSEcCtD
Zafirlukast—Thrombocytopenia—Cyclosporine—psoriasis	0.000218	0.00104	CcSEcCtD
Zafirlukast—Abdominal pain—Mycophenolic acid—psoriasis	0.000218	0.00104	CcSEcCtD
Zafirlukast—Body temperature increased—Mycophenolic acid—psoriasis	0.000218	0.00104	CcSEcCtD
Zafirlukast—Dizziness—Hydroxyurea—psoriasis	0.000218	0.00104	CcSEcCtD
Zafirlukast—Oedema—Mycophenolate mofetil—psoriasis	0.000218	0.00104	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR downstream signaling—CCL20—psoriasis	0.000217	0.00452	CbGpPWpGaD
Zafirlukast—Infection—Mycophenolate mofetil—psoriasis	0.000216	0.00103	CcSEcCtD
Zafirlukast—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000216	0.00449	CbGpPWpGaD
Zafirlukast—Eosinophilia—Methotrexate—psoriasis	0.000215	0.00102	CcSEcCtD
Zafirlukast—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000214	0.00444	CbGpPWpGaD
Zafirlukast—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000213	0.00443	CbGpPWpGaD
Zafirlukast—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000213	0.00443	CbGpPWpGaD
Zafirlukast—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000213	0.00102	CcSEcCtD
Zafirlukast—Ill-defined disorder—Triamcinolone—psoriasis	0.000212	0.00101	CcSEcCtD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000212	0.0044	CbGpPWpGaD
Zafirlukast—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000211	0.00438	CbGpPWpGaD
Zafirlukast—Vomiting—Hydroxyurea—psoriasis	0.000209	0.000999	CcSEcCtD
Zafirlukast—Discomfort—Prednisolone—psoriasis	0.000209	0.000999	CcSEcCtD
Zafirlukast—Angioedema—Triamcinolone—psoriasis	0.000209	0.000998	CcSEcCtD
Zafirlukast—Haemoglobin—Prednisone—psoriasis	0.000209	0.000996	CcSEcCtD
Zafirlukast—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000208	0.00433	CbGpPWpGaD
Zafirlukast—Abdominal discomfort—Methotrexate—psoriasis	0.000208	0.000992	CcSEcCtD
Zafirlukast—Haemorrhage—Prednisone—psoriasis	0.000208	0.000991	CcSEcCtD
Zafirlukast—Rash—Hydroxyurea—psoriasis	0.000207	0.000991	CcSEcCtD
Zafirlukast—Dermatitis—Hydroxyurea—psoriasis	0.000207	0.00099	CcSEcCtD
Zafirlukast—Myalgia—Hydrocortisone—psoriasis	0.000207	0.000987	CcSEcCtD
Zafirlukast—Malaise—Triamcinolone—psoriasis	0.000206	0.000985	CcSEcCtD
Zafirlukast—Headache—Hydroxyurea—psoriasis	0.000206	0.000985	CcSEcCtD
Zafirlukast—Discomfort—Hydrocortisone—psoriasis	0.000204	0.000976	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000203	0.00097	CcSEcCtD
Zafirlukast—Oedema—Prednisolone—psoriasis	0.000203	0.000969	CcSEcCtD
Zafirlukast—Neutropenia—Methotrexate—psoriasis	0.000203	0.000968	CcSEcCtD
Zafirlukast—Insomnia—Cyclosporine—psoriasis	0.000202	0.000963	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000198	0.000947	CcSEcCtD
Zafirlukast—Oedema—Hydrocortisone—psoriasis	0.000198	0.000946	CcSEcCtD
Zafirlukast—Asthenia—Mycophenolic acid—psoriasis	0.000198	0.000945	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling by GPCR—CCL20—psoriasis	0.000197	0.0041	CbGpPWpGaD
Zafirlukast—Infection—Hydrocortisone—psoriasis	0.000197	0.00094	CcSEcCtD
Zafirlukast—Insomnia—Mycophenolate mofetil—psoriasis	0.000197	0.00094	CcSEcCtD
Zafirlukast—Dyspepsia—Cyclosporine—psoriasis	0.000196	0.000937	CcSEcCtD
Zafirlukast—Nausea—Hydroxyurea—psoriasis	0.000195	0.000934	CcSEcCtD
Zafirlukast—Pruritus—Mycophenolic acid—psoriasis	0.000195	0.000931	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling Pathways—TAGAP—psoriasis	0.000195	0.00405	CbGpPWpGaD
Zafirlukast—Myalgia—Triamcinolone—psoriasis	0.000195	0.00093	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000192	0.000919	CcSEcCtD
Zafirlukast—Ill-defined disorder—Betamethasone—psoriasis	0.000192	0.000919	CcSEcCtD
Zafirlukast—Ill-defined disorder—Dexamethasone—psoriasis	0.000192	0.000919	CcSEcCtD
Zafirlukast—Discomfort—Triamcinolone—psoriasis	0.000192	0.000919	CcSEcCtD
Zafirlukast—Fatigue—Cyclosporine—psoriasis	0.000192	0.000918	CcSEcCtD
Zafirlukast—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000191	0.000915	CcSEcCtD
Zafirlukast—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000191	0.00397	CbGpPWpGaD
Zafirlukast—Pain—Cyclosporine—psoriasis	0.000191	0.000911	CcSEcCtD
Zafirlukast—Angioedema—Dexamethasone—psoriasis	0.00019	0.000905	CcSEcCtD
Zafirlukast—Angioedema—Betamethasone—psoriasis	0.00019	0.000905	CcSEcCtD
Zafirlukast—Diarrhoea—Mycophenolic acid—psoriasis	0.000189	0.000901	CcSEcCtD
Zafirlukast—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000188	0.00391	CbGpPWpGaD
Zafirlukast—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000188	0.000897	CcSEcCtD
Zafirlukast—Malaise—Dexamethasone—psoriasis	0.000187	0.000894	CcSEcCtD
Zafirlukast—Malaise—Betamethasone—psoriasis	0.000187	0.000894	CcSEcCtD
Zafirlukast—Oedema—Triamcinolone—psoriasis	0.000187	0.000891	CcSEcCtD
Zafirlukast—Pain—Mycophenolate mofetil—psoriasis	0.000186	0.000888	CcSEcCtD
Zafirlukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000186	0.00386	CbGpPWpGaD
Zafirlukast—Infection—Triamcinolone—psoriasis	0.000185	0.000885	CcSEcCtD
Zafirlukast—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000185	0.00384	CbGpPWpGaD
Zafirlukast—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000184	0.00382	CbGpPWpGaD
Zafirlukast—Feeling abnormal—Cyclosporine—psoriasis	0.000184	0.000878	CcSEcCtD
Zafirlukast—Insomnia—Prednisolone—psoriasis	0.000184	0.000877	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Cyclosporine—psoriasis	0.000182	0.000871	CcSEcCtD
Zafirlukast—Dizziness—Mycophenolic acid—psoriasis	0.000182	0.000871	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000181	0.000862	CcSEcCtD
Zafirlukast—Agranulocytosis—Methotrexate—psoriasis	0.00018	0.000861	CcSEcCtD
Zafirlukast—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000179	0.000856	CcSEcCtD
Zafirlukast—Insomnia—Hydrocortisone—psoriasis	0.000179	0.000856	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000178	0.00085	CcSEcCtD
Zafirlukast—Urticaria—Cyclosporine—psoriasis	0.000177	0.000846	CcSEcCtD
Zafirlukast—Myalgia—Dexamethasone—psoriasis	0.000177	0.000844	CcSEcCtD
Zafirlukast—Myalgia—Betamethasone—psoriasis	0.000177	0.000844	CcSEcCtD
Zafirlukast—Body temperature increased—Cyclosporine—psoriasis	0.000176	0.000842	CcSEcCtD
Zafirlukast—Abdominal pain—Cyclosporine—psoriasis	0.000176	0.000842	CcSEcCtD
Zafirlukast—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000175	0.00365	CbGpPWpGaD
Zafirlukast—Vomiting—Mycophenolic acid—psoriasis	0.000175	0.000837	CcSEcCtD
Zafirlukast—Discomfort—Dexamethasone—psoriasis	0.000174	0.000833	CcSEcCtD
Zafirlukast—Discomfort—Betamethasone—psoriasis	0.000174	0.000833	CcSEcCtD
Zafirlukast—Dyspepsia—Hydrocortisone—psoriasis	0.000174	0.000833	CcSEcCtD
Zafirlukast—Haemoglobin—Methotrexate—psoriasis	0.000174	0.000833	CcSEcCtD
Zafirlukast—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000174	0.00362	CbGpPWpGaD
Zafirlukast—Rash—Mycophenolic acid—psoriasis	0.000174	0.00083	CcSEcCtD
Zafirlukast—Dermatitis—Mycophenolic acid—psoriasis	0.000174	0.000829	CcSEcCtD
Zafirlukast—Pain—Prednisolone—psoriasis	0.000174	0.000829	CcSEcCtD
Zafirlukast—Haemorrhage—Methotrexate—psoriasis	0.000173	0.000828	CcSEcCtD
Zafirlukast—Hepatitis—Methotrexate—psoriasis	0.000173	0.000828	CcSEcCtD
Zafirlukast—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000173	0.0036	CbGpPWpGaD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000173	0.0036	CbGpPWpGaD
Zafirlukast—Urticaria—Mycophenolate mofetil—psoriasis	0.000173	0.000825	CcSEcCtD
Zafirlukast—Headache—Mycophenolic acid—psoriasis	0.000173	0.000825	CcSEcCtD
Zafirlukast—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000172	0.000821	CcSEcCtD
Zafirlukast—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000172	0.000821	CcSEcCtD
Zafirlukast—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000172	0.00357	CbGpPWpGaD
Zafirlukast—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000171	0.000817	CcSEcCtD
Zafirlukast—Fatigue—Hydrocortisone—psoriasis	0.000171	0.000816	CcSEcCtD
Zafirlukast—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.00017	0.00354	CbGpPWpGaD
Zafirlukast—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00017	0.000812	CcSEcCtD
Zafirlukast—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.00017	0.00353	CbGpPWpGaD
Zafirlukast—Pain—Hydrocortisone—psoriasis	0.000169	0.000809	CcSEcCtD
Zafirlukast—Oedema—Betamethasone—psoriasis	0.000169	0.000809	CcSEcCtD
Zafirlukast—Oedema—Dexamethasone—psoriasis	0.000169	0.000809	CcSEcCtD
Zafirlukast—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000169	0.00352	CbGpPWpGaD
Zafirlukast—Insomnia—Triamcinolone—psoriasis	0.000169	0.000806	CcSEcCtD
Zafirlukast—Infection—Betamethasone—psoriasis	0.000168	0.000803	CcSEcCtD
Zafirlukast—Infection—Dexamethasone—psoriasis	0.000168	0.000803	CcSEcCtD
Zafirlukast—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000168	0.00349	CbGpPWpGaD
Zafirlukast—Ill-defined disorder—Prednisone—psoriasis	0.000168	0.000801	CcSEcCtD
Zafirlukast—Feeling abnormal—Prednisolone—psoriasis	0.000167	0.000799	CcSEcCtD
Zafirlukast—Thrombocytopenia—Betamethasone—psoriasis	0.000166	0.000792	CcSEcCtD
Zafirlukast—Thrombocytopenia—Dexamethasone—psoriasis	0.000166	0.000792	CcSEcCtD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000166	0.00344	CbGpPWpGaD
Zafirlukast—Angioedema—Prednisone—psoriasis	0.000165	0.000788	CcSEcCtD
Zafirlukast—Hypersensitivity—Cyclosporine—psoriasis	0.000164	0.000785	CcSEcCtD
Zafirlukast—Dyspepsia—Triamcinolone—psoriasis	0.000164	0.000784	CcSEcCtD
Zafirlukast—Nausea—Mycophenolic acid—psoriasis	0.000164	0.000782	CcSEcCtD
Zafirlukast—Feeling abnormal—Hydrocortisone—psoriasis	0.000163	0.00078	CcSEcCtD
Zafirlukast—Malaise—Prednisone—psoriasis	0.000163	0.000778	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000162	0.000774	CcSEcCtD
Zafirlukast—Urticaria—Prednisolone—psoriasis	0.000161	0.00077	CcSEcCtD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000161	0.00335	CbGpPWpGaD
Zafirlukast—Fatigue—Triamcinolone—psoriasis	0.000161	0.000768	CcSEcCtD
Zafirlukast—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00016	0.000765	CcSEcCtD
Zafirlukast—Asthenia—Cyclosporine—psoriasis	0.00016	0.000764	CcSEcCtD
Zafirlukast—Pain—Triamcinolone—psoriasis	0.00016	0.000762	CcSEcCtD
Zafirlukast—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000159	0.0033	CbGpPWpGaD
Zafirlukast—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000159	0.0033	CbGpPWpGaD
Zafirlukast—Pruritus—Cyclosporine—psoriasis	0.000158	0.000753	CcSEcCtD
Zafirlukast—Urticaria—Hydrocortisone—psoriasis	0.000157	0.000752	CcSEcCtD
Zafirlukast—Body temperature increased—Hydrocortisone—psoriasis	0.000157	0.000748	CcSEcCtD
Zafirlukast—Abdominal pain—Hydrocortisone—psoriasis	0.000157	0.000748	CcSEcCtD
Zafirlukast—Asthenia—Mycophenolate mofetil—psoriasis	0.000156	0.000745	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling Pathways—HCAR2—psoriasis	0.000156	0.00324	CbGpPWpGaD
Zafirlukast—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000154	0.000737	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000154	0.000737	CcSEcCtD
Zafirlukast—Pruritus—Mycophenolate mofetil—psoriasis	0.000154	0.000735	CcSEcCtD
Zafirlukast—Arthralgia—Prednisone—psoriasis	0.000154	0.000735	CcSEcCtD
Zafirlukast—Myalgia—Prednisone—psoriasis	0.000154	0.000735	CcSEcCtD
Zafirlukast—Feeling abnormal—Triamcinolone—psoriasis	0.000154	0.000734	CcSEcCtD
Zafirlukast—Insomnia—Betamethasone—psoriasis	0.000153	0.000731	CcSEcCtD
Zafirlukast—Insomnia—Dexamethasone—psoriasis	0.000153	0.000731	CcSEcCtD
Zafirlukast—Diarrhoea—Cyclosporine—psoriasis	0.000153	0.000729	CcSEcCtD
Zafirlukast—Discomfort—Prednisone—psoriasis	0.000152	0.000726	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR downstream signaling—CCL20—psoriasis	0.000151	0.00313	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Prednisolone—psoriasis	0.000149	0.000714	CcSEcCtD
Zafirlukast—Dyspepsia—Betamethasone—psoriasis	0.000149	0.000712	CcSEcCtD
Zafirlukast—Dyspepsia—Dexamethasone—psoriasis	0.000149	0.000712	CcSEcCtD
Zafirlukast—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000149	0.000711	CcSEcCtD
Zafirlukast—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000149	0.00309	CbGpPWpGaD
Zafirlukast—Urticaria—Triamcinolone—psoriasis	0.000148	0.000708	CcSEcCtD
Zafirlukast—Body temperature increased—Triamcinolone—psoriasis	0.000147	0.000705	CcSEcCtD
Zafirlukast—Dizziness—Cyclosporine—psoriasis	0.000147	0.000704	CcSEcCtD
Zafirlukast—Oedema—Prednisone—psoriasis	0.000147	0.000704	CcSEcCtD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000147	0.00305	CbGpPWpGaD
Zafirlukast—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000147	0.00305	CbGpPWpGaD
Zafirlukast—Infection—Prednisone—psoriasis	0.000146	0.0007	CcSEcCtD
Zafirlukast—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000146	0.00304	CbGpPWpGaD
Zafirlukast—Gastrointestinal disorder—Betamethasone—psoriasis	0.000146	0.000698	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000146	0.000698	CcSEcCtD
Zafirlukast—Back pain—Methotrexate—psoriasis	0.000146	0.000698	CcSEcCtD
Zafirlukast—Hypersensitivity—Hydrocortisone—psoriasis	0.000146	0.000697	CcSEcCtD
Zafirlukast—Fatigue—Dexamethasone—psoriasis	0.000146	0.000697	CcSEcCtD
Zafirlukast—Fatigue—Betamethasone—psoriasis	0.000146	0.000697	CcSEcCtD
Zafirlukast—Pain—Betamethasone—psoriasis	0.000145	0.000692	CcSEcCtD
Zafirlukast—Pain—Dexamethasone—psoriasis	0.000145	0.000692	CcSEcCtD
Zafirlukast—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000144	0.003	CbGpPWpGaD
Zafirlukast—Dizziness—Mycophenolate mofetil—psoriasis	0.000144	0.000687	CcSEcCtD
Zafirlukast—Asthenia—Hydrocortisone—psoriasis	0.000142	0.000679	CcSEcCtD
Zafirlukast—Vomiting—Cyclosporine—psoriasis	0.000142	0.000677	CcSEcCtD
Zafirlukast—Rash—Cyclosporine—psoriasis	0.000141	0.000671	CcSEcCtD
Zafirlukast—Dermatitis—Cyclosporine—psoriasis	0.00014	0.000671	CcSEcCtD
Zafirlukast—Pruritus—Hydrocortisone—psoriasis	0.00014	0.00067	CcSEcCtD
Zafirlukast—Ill-defined disorder—Methotrexate—psoriasis	0.00014	0.000669	CcSEcCtD
Zafirlukast—Headache—Cyclosporine—psoriasis	0.00014	0.000667	CcSEcCtD
Zafirlukast—Feeling abnormal—Dexamethasone—psoriasis	0.00014	0.000666	CcSEcCtD
Zafirlukast—Feeling abnormal—Betamethasone—psoriasis	0.00014	0.000666	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Betamethasone—psoriasis	0.000138	0.000661	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Dexamethasone—psoriasis	0.000138	0.000661	CcSEcCtD
Zafirlukast—Vomiting—Mycophenolate mofetil—psoriasis	0.000138	0.000661	CcSEcCtD
Zafirlukast—Hypersensitivity—Triamcinolone—psoriasis	0.000137	0.000657	CcSEcCtD
Zafirlukast—Rash—Mycophenolate mofetil—psoriasis	0.000137	0.000655	CcSEcCtD
Zafirlukast—Dermatitis—Mycophenolate mofetil—psoriasis	0.000137	0.000654	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling by GPCR—CCL20—psoriasis	0.000137	0.00285	CbGpPWpGaD
Zafirlukast—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000136	0.00284	CbGpPWpGaD
Zafirlukast—Headache—Mycophenolate mofetil—psoriasis	0.000136	0.000651	CcSEcCtD
Zafirlukast—Malaise—Methotrexate—psoriasis	0.000136	0.00065	CcSEcCtD
Zafirlukast—Diarrhoea—Hydrocortisone—psoriasis	0.000136	0.000648	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling Pathways—TAGAP—psoriasis	0.000135	0.00281	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000135	0.0028	CbGpPWpGaD
Zafirlukast—Urticaria—Dexamethasone—psoriasis	0.000134	0.000642	CcSEcCtD
Zafirlukast—Urticaria—Betamethasone—psoriasis	0.000134	0.000642	CcSEcCtD
Zafirlukast—Musculoskeletal discomfort—Prednisone—psoriasis	0.000134	0.000642	CcSEcCtD
Zafirlukast—Dizziness—Prednisolone—psoriasis	0.000134	0.000641	CcSEcCtD
Zafirlukast—Asthenia—Triamcinolone—psoriasis	0.000134	0.000639	CcSEcCtD
Zafirlukast—Abdominal pain—Betamethasone—psoriasis	0.000134	0.000639	CcSEcCtD
Zafirlukast—Abdominal pain—Dexamethasone—psoriasis	0.000134	0.000639	CcSEcCtD
Zafirlukast—Body temperature increased—Dexamethasone—psoriasis	0.000134	0.000639	CcSEcCtD
Zafirlukast—Body temperature increased—Betamethasone—psoriasis	0.000134	0.000639	CcSEcCtD
Zafirlukast—Insomnia—Prednisone—psoriasis	0.000133	0.000637	CcSEcCtD
Zafirlukast—Nausea—Cyclosporine—psoriasis	0.000132	0.000633	CcSEcCtD
Zafirlukast—Pruritus—Triamcinolone—psoriasis	0.000132	0.000631	CcSEcCtD
Zafirlukast—Dizziness—Hydrocortisone—psoriasis	0.000131	0.000626	CcSEcCtD
Zafirlukast—Dyspepsia—Prednisone—psoriasis	0.00013	0.00062	CcSEcCtD
Zafirlukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000129	0.00269	CbGpPWpGaD
Zafirlukast—Nausea—Mycophenolate mofetil—psoriasis	0.000129	0.000617	CcSEcCtD
Zafirlukast—Myalgia—Methotrexate—psoriasis	0.000129	0.000614	CcSEcCtD
Zafirlukast—Arthralgia—Methotrexate—psoriasis	0.000129	0.000614	CcSEcCtD
Zafirlukast—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000128	0.00267	CbGpPWpGaD
Zafirlukast—Rash—Prednisolone—psoriasis	0.000128	0.000611	CcSEcCtD
Zafirlukast—Dermatitis—Prednisolone—psoriasis	0.000128	0.00061	CcSEcCtD
Zafirlukast—Fatigue—Prednisone—psoriasis	0.000127	0.000607	CcSEcCtD
Zafirlukast—Headache—Prednisolone—psoriasis	0.000127	0.000607	CcSEcCtD
Zafirlukast—Discomfort—Methotrexate—psoriasis	0.000127	0.000607	CcSEcCtD
Zafirlukast—Vomiting—Hydrocortisone—psoriasis	0.000126	0.000602	CcSEcCtD
Zafirlukast—Rash—Hydrocortisone—psoriasis	0.000125	0.000597	CcSEcCtD
Zafirlukast—Dermatitis—Hydrocortisone—psoriasis	0.000125	0.000596	CcSEcCtD
Zafirlukast—Headache—Hydrocortisone—psoriasis	0.000124	0.000593	CcSEcCtD
Zafirlukast—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.000124	0.00258	CbGpPWpGaD
Zafirlukast—Dizziness—Triamcinolone—psoriasis	0.000123	0.000589	CcSEcCtD
Zafirlukast—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	0.000123	0.00255	CbGpPWpGaD
Zafirlukast—Infection—Methotrexate—psoriasis	0.000122	0.000585	CcSEcCtD
Zafirlukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000122	0.00254	CbGpPWpGaD
Zafirlukast—Feeling abnormal—Prednisone—psoriasis	0.000121	0.00058	CcSEcCtD
Zafirlukast—Asthenia—Betamethasone—psoriasis	0.000121	0.00058	CcSEcCtD
Zafirlukast—Asthenia—Dexamethasone—psoriasis	0.000121	0.00058	CcSEcCtD
Zafirlukast—Thrombocytopenia—Methotrexate—psoriasis	0.000121	0.000576	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Prednisone—psoriasis	0.000121	0.000576	CcSEcCtD
Zafirlukast—Nausea—Prednisolone—psoriasis	0.000121	0.000576	CcSEcCtD
Zafirlukast—Pruritus—Betamethasone—psoriasis	0.00012	0.000572	CcSEcCtD
Zafirlukast—Pruritus—Dexamethasone—psoriasis	0.00012	0.000572	CcSEcCtD
Zafirlukast—Vomiting—Triamcinolone—psoriasis	0.000119	0.000567	CcSEcCtD
Zafirlukast—Nausea—Hydrocortisone—psoriasis	0.000118	0.000562	CcSEcCtD
Zafirlukast—Rash—Triamcinolone—psoriasis	0.000118	0.000562	CcSEcCtD
Zafirlukast—Dermatitis—Triamcinolone—psoriasis	0.000118	0.000561	CcSEcCtD
Zafirlukast—Urticaria—Prednisone—psoriasis	0.000117	0.000559	CcSEcCtD
Zafirlukast—Headache—Triamcinolone—psoriasis	0.000117	0.000558	CcSEcCtD
Zafirlukast—CYSLTR2—Signaling Pathways—CCL20—psoriasis	0.000117	0.00242	CbGpPWpGaD
Zafirlukast—Abdominal pain—Prednisone—psoriasis	0.000117	0.000557	CcSEcCtD
Zafirlukast—Body temperature increased—Prednisone—psoriasis	0.000117	0.000557	CcSEcCtD
Zafirlukast—Diarrhoea—Betamethasone—psoriasis	0.000116	0.000553	CcSEcCtD
Zafirlukast—Diarrhoea—Dexamethasone—psoriasis	0.000116	0.000553	CcSEcCtD
Zafirlukast—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000115	0.00238	CbGpPWpGaD
Zafirlukast—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000113	0.00235	CbGpPWpGaD
Zafirlukast—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000112	0.000536	CcSEcCtD
Zafirlukast—Dizziness—Dexamethasone—psoriasis	0.000112	0.000535	CcSEcCtD
Zafirlukast—Dizziness—Betamethasone—psoriasis	0.000112	0.000535	CcSEcCtD
Zafirlukast—Insomnia—Methotrexate—psoriasis	0.000111	0.000532	CcSEcCtD
Zafirlukast—Nausea—Triamcinolone—psoriasis	0.000111	0.000529	CcSEcCtD
Zafirlukast—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000111	0.0023	CbGpPWpGaD
Zafirlukast—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.00011	0.00229	CbGpPWpGaD
Zafirlukast—Hypersensitivity—Prednisone—psoriasis	0.000109	0.000519	CcSEcCtD
Zafirlukast—Dyspepsia—Methotrexate—psoriasis	0.000108	0.000518	CcSEcCtD
Zafirlukast—Vomiting—Betamethasone—psoriasis	0.000108	0.000514	CcSEcCtD
Zafirlukast—Vomiting—Dexamethasone—psoriasis	0.000108	0.000514	CcSEcCtD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000107	0.00222	CbGpPWpGaD
Zafirlukast—Rash—Dexamethasone—psoriasis	0.000107	0.00051	CcSEcCtD
Zafirlukast—Rash—Betamethasone—psoriasis	0.000107	0.00051	CcSEcCtD
Zafirlukast—Dermatitis—Dexamethasone—psoriasis	0.000107	0.000509	CcSEcCtD
Zafirlukast—Dermatitis—Betamethasone—psoriasis	0.000107	0.000509	CcSEcCtD
Zafirlukast—Gastrointestinal disorder—Methotrexate—psoriasis	0.000106	0.000508	CcSEcCtD
Zafirlukast—Fatigue—Methotrexate—psoriasis	0.000106	0.000507	CcSEcCtD
Zafirlukast—Headache—Betamethasone—psoriasis	0.000106	0.000507	CcSEcCtD
Zafirlukast—Headache—Dexamethasone—psoriasis	0.000106	0.000507	CcSEcCtD
Zafirlukast—Asthenia—Prednisone—psoriasis	0.000106	0.000505	CcSEcCtD
Zafirlukast—Pain—Methotrexate—psoriasis	0.000105	0.000503	CcSEcCtD
Zafirlukast—Pruritus—Prednisone—psoriasis	0.000104	0.000498	CcSEcCtD
Zafirlukast—CYSLTR2—GPCR ligand binding—CXCL8—psoriasis	0.000104	0.00216	CbGpPWpGaD
Zafirlukast—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000103	0.00215	CbGpPWpGaD
Zafirlukast—Feeling abnormal—Methotrexate—psoriasis	0.000102	0.000485	CcSEcCtD
Zafirlukast—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000101	0.0021	CbGpPWpGaD
Zafirlukast—Diarrhoea—Prednisone—psoriasis	0.000101	0.000482	CcSEcCtD
Zafirlukast—Gastrointestinal pain—Methotrexate—psoriasis	0.000101	0.000481	CcSEcCtD
Zafirlukast—Nausea—Betamethasone—psoriasis	0.000101	0.00048	CcSEcCtD
Zafirlukast—Nausea—Dexamethasone—psoriasis	0.000101	0.00048	CcSEcCtD
Zafirlukast—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.9e-05	0.00206	CbGpPWpGaD
Zafirlukast—Urticaria—Methotrexate—psoriasis	9.79e-05	0.000468	CcSEcCtD
Zafirlukast—Dizziness—Prednisone—psoriasis	9.75e-05	0.000466	CcSEcCtD
Zafirlukast—Abdominal pain—Methotrexate—psoriasis	9.74e-05	0.000465	CcSEcCtD
Zafirlukast—Body temperature increased—Methotrexate—psoriasis	9.74e-05	0.000465	CcSEcCtD
Zafirlukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.46e-05	0.00197	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	9.43e-05	0.00196	CbGpPWpGaD
Zafirlukast—Vomiting—Prednisone—psoriasis	9.37e-05	0.000448	CcSEcCtD
Zafirlukast—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	9.33e-05	0.00194	CbGpPWpGaD
Zafirlukast—Rash—Prednisone—psoriasis	9.3e-05	0.000444	CcSEcCtD
Zafirlukast—Dermatitis—Prednisone—psoriasis	9.29e-05	0.000444	CcSEcCtD
Zafirlukast—Headache—Prednisone—psoriasis	9.24e-05	0.000441	CcSEcCtD
Zafirlukast—Hypersensitivity—Methotrexate—psoriasis	9.08e-05	0.000434	CcSEcCtD
Zafirlukast—Asthenia—Methotrexate—psoriasis	8.84e-05	0.000422	CcSEcCtD
Zafirlukast—Nausea—Prednisone—psoriasis	8.76e-05	0.000418	CcSEcCtD
Zafirlukast—Pruritus—Methotrexate—psoriasis	8.72e-05	0.000416	CcSEcCtD
Zafirlukast—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	8.57e-05	0.00178	CbGpPWpGaD
Zafirlukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.53e-05	0.00177	CbGpPWpGaD
Zafirlukast—Diarrhoea—Methotrexate—psoriasis	8.43e-05	0.000403	CcSEcCtD
Zafirlukast—Dizziness—Methotrexate—psoriasis	8.15e-05	0.000389	CcSEcCtD
Zafirlukast—CYSLTR1—Signaling Pathways—CCL20—psoriasis	8.08e-05	0.00168	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	7.85e-05	0.00163	CbGpPWpGaD
Zafirlukast—Vomiting—Methotrexate—psoriasis	7.83e-05	0.000374	CcSEcCtD
Zafirlukast—Rash—Methotrexate—psoriasis	7.77e-05	0.000371	CcSEcCtD
Zafirlukast—Dermatitis—Methotrexate—psoriasis	7.76e-05	0.000371	CcSEcCtD
Zafirlukast—Headache—Methotrexate—psoriasis	7.72e-05	0.000369	CcSEcCtD
Zafirlukast—Nausea—Methotrexate—psoriasis	7.32e-05	0.00035	CcSEcCtD
Zafirlukast—CYSLTR1—GPCR ligand binding—CXCL8—psoriasis	7.2e-05	0.0015	CbGpPWpGaD
Zafirlukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.17e-05	0.00149	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.12e-05	0.00148	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—NDUFA5—psoriasis	6.93e-05	0.00144	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—NDUFA5—psoriasis	6.65e-05	0.00138	CbGpPWpGaD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	6.44e-05	0.00134	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—SOCS1—psoriasis	6.42e-05	0.00134	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.2e-05	0.00129	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.15e-05	0.00128	CbGpPWpGaD
Zafirlukast—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	6.14e-05	0.00128	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—TYK2—psoriasis	6.12e-05	0.00127	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	6.11e-05	0.00127	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.92e-05	0.00123	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CYP2S1—psoriasis	5.89e-05	0.00122	CbGpPWpGaD
Zafirlukast—CYSLTR2—GPCR downstream signaling—CXCL8—psoriasis	5.87e-05	0.00122	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CYP2S1—psoriasis	5.66e-05	0.00118	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.38e-05	0.00112	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—CXCL8—psoriasis	5.33e-05	0.00111	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—NDUFA5—psoriasis	4.97e-05	0.00103	CbGpPWpGaD
Zafirlukast—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	4.93e-05	0.00102	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—LEP—psoriasis	4.74e-05	0.000985	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—APOE—psoriasis	4.74e-05	0.000985	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.61e-05	0.000958	CbGpPWpGaD
Zafirlukast—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.61e-05	0.000958	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—SOCS1—psoriasis	4.45e-05	0.000926	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—NFKBIA—psoriasis	4.42e-05	0.000918	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—NDUFA5—psoriasis	4.3e-05	0.000894	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—TYK2—psoriasis	4.24e-05	0.000882	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CYP2S1—psoriasis	4.23e-05	0.000879	CbGpPWpGaD
Zafirlukast—CYSLTR1—GPCR downstream signaling—CXCL8—psoriasis	4.07e-05	0.000846	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.01e-05	0.000833	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—NDUFA5—psoriasis	3.84e-05	0.000798	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—CXCL8—psoriasis	3.7e-05	0.000768	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CYP2S1—psoriasis	3.65e-05	0.00076	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TYK2—psoriasis	3.62e-05	0.000752	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.58e-05	0.000744	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—NDUFA5—psoriasis	3.53e-05	0.000734	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—NDUFA5—psoriasis	3.5e-05	0.000727	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—LEP—psoriasis	3.29e-05	0.000683	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—APOE—psoriasis	3.29e-05	0.000683	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CYP2S1—psoriasis	3.26e-05	0.000678	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.26e-05	0.000678	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—CXCL8—psoriasis	3.15e-05	0.000655	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—NFKBIA—psoriasis	3.06e-05	0.000636	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CYP2S1—psoriasis	3e-05	0.000624	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling by GPCR—IL6—psoriasis	3e-05	0.000623	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—NDUFA5—psoriasis	2.99e-05	0.000621	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CYP2S1—psoriasis	2.97e-05	0.000618	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.96e-05	0.000616	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—JUN—psoriasis	2.93e-05	0.000609	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CARM1—psoriasis	2.88e-05	0.000598	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—NFKB1—psoriasis	2.82e-05	0.000586	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.79e-05	0.000579	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CARM1—psoriasis	2.76e-05	0.000574	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.58e-05	0.000537	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—VEGFA—psoriasis	2.56e-05	0.000532	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CYP2S1—psoriasis	2.54e-05	0.000528	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—STAT3—psoriasis	2.53e-05	0.000527	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TYK2—psoriasis	2.51e-05	0.000521	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—NDUFA5—psoriasis	2.31e-05	0.00048	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—CXCL8—psoriasis	2.18e-05	0.000454	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling by GPCR—IL6—psoriasis	2.08e-05	0.000432	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CARM1—psoriasis	2.06e-05	0.000429	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—JUN—psoriasis	2.03e-05	0.000422	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CYP2S1—psoriasis	1.96e-05	0.000408	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—NFKB1—psoriasis	1.95e-05	0.000406	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—TP53—psoriasis	1.93e-05	0.000402	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.92e-05	0.000398	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CARM1—psoriasis	1.78e-05	0.000371	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—VEGFA—psoriasis	1.77e-05	0.000369	CbGpPWpGaD
Zafirlukast—CYSLTR2—Signaling Pathways—IL6—psoriasis	1.77e-05	0.000368	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—CAT—psoriasis	1.77e-05	0.000368	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—STAT3—psoriasis	1.76e-05	0.000365	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.71e-05	0.000355	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—CAT—psoriasis	1.7e-05	0.000353	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.67e-05	0.000347	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CARM1—psoriasis	1.59e-05	0.000331	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.56e-05	0.000324	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.49e-05	0.00031	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CARM1—psoriasis	1.47e-05	0.000305	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CARM1—psoriasis	1.45e-05	0.000302	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—APOE—psoriasis	1.37e-05	0.000286	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.36e-05	0.000282	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—TP53—psoriasis	1.34e-05	0.000279	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.33e-05	0.000277	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—APOE—psoriasis	1.32e-05	0.000275	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—CAT—psoriasis	1.27e-05	0.000264	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CARM1—psoriasis	1.24e-05	0.000258	CbGpPWpGaD
Zafirlukast—CYSLTR1—Signaling Pathways—IL6—psoriasis	1.23e-05	0.000255	CbGpPWpGaD
Zafirlukast—ABCG2—Metabolism—PPARG—psoriasis	1.2e-05	0.000249	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.16e-05	0.000241	CbGpPWpGaD
Zafirlukast—PTGS1—Metabolism—PPARG—psoriasis	1.15e-05	0.000239	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—CAT—psoriasis	1.1e-05	0.000228	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—APOE—psoriasis	9.87e-06	0.000205	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—CAT—psoriasis	9.8e-06	0.000204	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CARM1—psoriasis	9.58e-06	0.000199	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—CAT—psoriasis	9.01e-06	0.000187	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—CAT—psoriasis	8.93e-06	0.000186	CbGpPWpGaD
Zafirlukast—CYP2E1—Metabolism—PPARG—psoriasis	8.59e-06	0.000179	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—APOE—psoriasis	8.53e-06	0.000177	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—CAT—psoriasis	7.63e-06	0.000159	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—APOE—psoriasis	7.61e-06	0.000158	CbGpPWpGaD
Zafirlukast—CYP2C8—Metabolism—PPARG—psoriasis	7.43e-06	0.000154	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—APOE—psoriasis	7e-06	0.000146	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—APOE—psoriasis	6.94e-06	0.000144	CbGpPWpGaD
Zafirlukast—CYP2C19—Metabolism—PPARG—psoriasis	6.63e-06	0.000138	CbGpPWpGaD
Zafirlukast—CYP2D6—Metabolism—PPARG—psoriasis	6.1e-06	0.000127	CbGpPWpGaD
Zafirlukast—CYP2C9—Metabolism—PPARG—psoriasis	6.05e-06	0.000126	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—APOE—psoriasis	5.93e-06	0.000123	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—CAT—psoriasis	5.89e-06	0.000122	CbGpPWpGaD
Zafirlukast—CYP1A2—Metabolism—PPARG—psoriasis	5.17e-06	0.000107	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—APOE—psoriasis	4.58e-06	9.52e-05	CbGpPWpGaD
Zafirlukast—CYP3A4—Metabolism—PPARG—psoriasis	3.99e-06	8.29e-05	CbGpPWpGaD
